The Florida Society of Rheumatology (FSR) has joined leading medical organizations across the country in signing onto a letter urging Congress to take meaningful action on pharmacy benefit manager (PBM) reform before the end of 2025. FSR leadership recognizes the serious impact that rising health care costs have on Floridians, with recent surveys showing that 80% of residents worry about their ability to afford care.
The letter emphasizes that PBMs play a major role in driving up costs by creating formularies that favor higher-priced medications. Six PBMs now control 94% of all prescription drug claims in the U.S., consolidating power among insurers, PBMs, and pharmacies, and limiting the decision-making ability of patients, physicians, and community pharmacists. A recent Federal Trade Commission report confirmed that PBMs often design formularies to maximize their own profits, not patient benefit.
Congress has multiple bipartisan bills ready to address these harmful practices, including the PBM Reform Act of 2025 (H.R. 4317), introduced by Rep. Buddy Carter. These reforms would break the link between PBM profits and drug prices by requiring flat, fair fees for PBM services; ensure that rebates and discounts are passed through to the consumer at the point of sale; and streamline utilization management protocols to improve access and reduce administrative burdens.
FSR leadership is proud to stand with other organizations in calling for swift congressional action on PBM reform and urges member of Congress to support H.R. 4317 by cosponsoring this important legislation.
Email to a Friend